Trials / Completed
CompletedNCT01972763
Ranibizumab for Recalcitrant Wet Age-related Macular Degeneration in Eyes Previously Switched From Bevacizumab and/or Ranibizumab to Aflibercept.
- Status
- Completed
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 12 (actual)
- Sponsor
- Northern California Retina Vitreous Associates · Academic / Other
- Sex
- All
- Age
- 50 Years
- Healthy volunteers
- Accepted
Summary
The purpose of the study is to determine the effectiveness of Ranibizumab 0.5 mg or 1.0 mg in subjects who were previously treated with Bevacizumab and subsequently switched to Aflibercept. These subjects have demonstrated a sub-optimal therapeutic response to the previous therapies; therefore, the study aims to see if Ranibizumab may have a greater treatment effect.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Ranibizumab | Ranibizumab is formulated as a sterile solution and will be used in the case of an intervention. |
Timeline
- Start date
- 2013-10-01
- Primary completion
- 2018-07-01
- Completion
- 2018-07-01
- First posted
- 2013-10-30
- Last updated
- 2019-02-05
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT01972763. Inclusion in this directory is not an endorsement.